Forum Financial Management LP Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Forum Financial Management LP lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 31.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,409 shares of the company's stock after purchasing an additional 7,826 shares during the period. Forum Financial Management LP's holdings in Johnson & Johnson were worth $4,687,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson in the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at approximately $32,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $33,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $36,000. 69.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 0.3%

JNJ stock traded up $0.51 during midday trading on Monday, reaching $153.12. The company's stock had a trading volume of 6,727,130 shares, compared to its average volume of 7,965,146. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market capitalization of $368.41 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.56 and a beta of 0.42. The stock has a fifty day simple moving average of $155.24 and a two-hundred day simple moving average of $153.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.40%. Johnson & Johnson's payout ratio is 57.84%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Bank of America decreased their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Barclays lowered their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Raymond James decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.